NCT00130728View on ClinicalTrials.gov

A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

636

Participants

Timeline

Start Date

June 8, 2005

Primary Completion Date

July 15, 2008

Study Completion Date

December 23, 2019

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

bevacizumab

intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle

DRUG

erlotinib HCl

oral erlotinib HCl 150 mg/day orally

DRUG

placebo

intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle

Trial Locations (4)

21401

Anne Arundel Health System Research Instit-Annapolis Oncology Ctr, Annapolis

30607

University Cancer & Blood Center, LLC; Research, Athens

66160

University of Kansas Medical Center, Kansas City

94589

Kaiser Permanente - Vallejo, Vallejo

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY